5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]thiazolidine-2,4-dione | 199113-77-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]thiazolidine-2,4-dione
• 英文别名: 5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenyl methylene]thiazolidine-2,4-dione；5-[[4-[2-(4-methyl-6-oxo-2-propylpyrimidin-1-yl)ethoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 199113-77-4
• 化学式: C₂₀H₂₁N₃O₄S
• 分子量: 399.47
• InChiKey: JNMCTUBKLMLHPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]thiazolidine-2,4-dione 在 palladium on activated charcoal 氢气 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以92%的产率得到5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  新型含噻唑烷二酮衍生物的嘧啶酮的合成及生物活性。

  摘要：

  合成了一系列噻唑烷二酮的嘧啶酮衍生物。在胰岛素抵抗，高血糖和肥胖的db / db小鼠中评估了它们的生物学活性。在HEK 293T细胞中进行了体外PPARγ激活测定。PMT13在该系列中表现出最好的生物活性。PMT13（5- [4- [2- [2-乙基-4-甲基-6-氧代-1,6-二氢-1-嘧啶基]乙氧基]苯基甲基]噻唑烷-2,4-二酮）血浆葡萄糖水平更高， db / db小鼠的甘油三酸酯和胰岛素降低活性高于罗格列酮和吡格列酮。PMT13显示出比标准化合物更好的PPARγ反式激活。Wistar大鼠的药代动力学研究表明，PMT13具有良好的全身性暴露。在Wistar大鼠中进行的28天口服毒性研究未显示任何与治疗相关的不良反应。

  DOI：

  10.1016/s0968-0896(02)00107-4
• 作为产物：
  描述：

  4-甲基-2-丙基-1,6-二氢嘧啶-6-酮 在 哌啶 、 sodium hydride 、 苯甲酸 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 18.0h， 生成 5-[4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]phenylmethylene]thiazolidine-2,4-dione
  参考文献：
  名称：

  新型含噻唑烷二酮衍生物的嘧啶酮的合成及生物活性。

  摘要：

  合成了一系列噻唑烷二酮的嘧啶酮衍生物。在胰岛素抵抗，高血糖和肥胖的db / db小鼠中评估了它们的生物学活性。在HEK 293T细胞中进行了体外PPARγ激活测定。PMT13在该系列中表现出最好的生物活性。PMT13（5- [4- [2- [2-乙基-4-甲基-6-氧代-1,6-二氢-1-嘧啶基]乙氧基]苯基甲基]噻唑烷-2,4-二酮）血浆葡萄糖水平更高， db / db小鼠的甘油三酸酯和胰岛素降低活性高于罗格列酮和吡格列酮。PMT13显示出比标准化合物更好的PPARγ反式激活。Wistar大鼠的药代动力学研究表明，PMT13具有良好的全身性暴露。在Wistar大鼠中进行的28天口服毒性研究未显示任何与治疗相关的不良反应。

  DOI：

  10.1016/s0968-0896(02)00107-4

文献信息

• Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
  申请人：Dr. Reddy's Research Foundation

  公开号：US06310069B1

  公开（公告）日：2001-10-30

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及新型抗糖尿病化合物及其互变异构体、衍生物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药用可接受盐、药用可接受溶剂和含有它们的药用组合物。
• Heterocyclic compounds, process for their preparation and pharmaceutical
  申请人：Dr. Reddy's Research Foundation

  公开号：US05985884A1

  公开（公告）日：1999-11-16

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、衍生物、立体异构体、多形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂和含有它们的制药组合物。##STR1##
• Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
  申请人：DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC.

  公开号：US20010031759A1

  公开（公告）日：2001-10-18

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. 1

  本发明涉及一种新型抗糖尿病化合物，其互变异构体、衍生物、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化合物以及含有它们的药学上可接受的组合物。本发明特别涉及一种一般式（I）的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂化合物和含有它们的药物组合物。1
• Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
  申请人：Lohray Bhushan Vidya

  公开号：US20050032864A1

  公开（公告）日：2005-02-10

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、它们的衍生物、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、药学上可接受的溶剂化物和含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂化物和含有它们的药物组合物。
• Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
  申请人：Dr. Reddy's Research Foundation

  公开号：US06372750B2

  公开（公告）日：2002-04-16

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、衍生物、立体异构体、多晶形态、药用盐、药用溶剂化物和含有它们的药用组合物。本发明特别涉及一般式（I）的新型氮杂环戊二酮衍生物及其药用盐、药用溶剂化物和含有它们的药用组合物。